Coya Therapeutics reports $32.6M cash at Dec 31, 2023; receives $7.5M from Dr. Reddy's in Jan 2024

Coya Therapeutics, Inc.

Cash and equivalents $32.6M as of Dec 31, 2023; pro forma $40.1M after $7.5M received from Dr. Reddy's in Jan 2024.
Milestone payments: $4.2M upon FDA acceptance of IND for COYA 302 (ALS) and $4.2M upon first patient dosed in Phase 2.
Anticipates IND filing in H1 2024 and first patient dosing in H2 2024 for COYA 302 in ALS.
Company expects current cash runway to fund operations into 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.